Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia
出版年份 2022 全文链接
标题
Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia
作者
关键词
Resistance, 5-azacytidine, 5-aza-2'-deoxycytidine, Hypomethylating agents, Acute myeloid leukemia, Myelodysplastic syndromes
出版物
DRUG RESISTANCE UPDATES
Volume -, Issue -, Pages 100805
出版商
Elsevier BV
发表日期
2022-01-21
DOI
10.1016/j.drup.2022.100805
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance
- (2021) May Levin et al. Cancer Cell International
- Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance
- (2021) Jing-Quan Wang et al. DRUG RESISTANCE UPDATES
- Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents
- (2021) Ľuboš Janotka et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Novel nanomedicines to overcome cancer multidrug resistance
- (2021) Zhenwei Su et al. DRUG RESISTANCE UPDATES
- The role of endolysosomal trafficking in anticancer drug resistance
- (2021) Noor A. Hussein et al. DRUG RESISTANCE UPDATES
- Exposure to hypomethylating 5-aza-2′-deoxycytidine (decitabine) causes rapid, severe DNA damage, telomere elongation and mitotic dysfunction in human WIL2-NS cells
- (2021) Caroline Bull et al. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
- Nanomedicine to target multidrug resistant tumors
- (2020) Elise Lepeltier et al. DRUG RESISTANCE UPDATES
- Targeting apoptosis in cancer therapy
- (2020) Benedito A. Carneiro et al. Nature Reviews Clinical Oncology
- Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia
- (2020) Emily Gruber et al. LEUKEMIA
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action
- (2020) Ellen J. B. Derissen et al. CLINICAL PHARMACOKINETICS
- Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance
- (2020) Nir Shahar et al. DRUG RESISTANCE UPDATES
- A guide to plasma membrane solute carrier proteins
- (2020) Mattia D. Pizzagalli et al. FEBS Journal
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
- (2020) Courtney D DiNardo et al. Lancet Haematology
- Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS
- (2020) Gerwin Huls et al. Blood Advances
- DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy
- (2020) Larissa Costa de Almeida et al. Cancer Genetics
- Platinum Resistance in Ovarian Cancer: Role of DNA Repair
- (2019) Giovanna Damia et al. Cancers
- A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
- (2019) Marie Sébert et al. HAEMATOLOGICA
- Clinical update on hypomethylating agents
- (2019) Matthieu Duchmann et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance
- (2019) Ladan Mashouri et al. Molecular Cancer
- Can we predict responsiveness to hypomethylating agents in AML?
- (2019) Julia Stomper et al. SEMINARS IN HEMATOLOGY
- Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine
- (2019) May Levin et al. Cell Death & Disease
- IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer
- (2019) Carlota Colomer et al. MOLECULAR CELL
- The multi-factorial nature of clinical multidrug resistance in cancer
- (2019) Yehuda G. Assaraf et al. DRUG RESISTANCE UPDATES
- DNA repair in cancer initiation, progression, and therapy—a double-edged sword
- (2019) Katarzyna Kiwerska et al. JOURNAL OF APPLIED GENETICS
- Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
- (2019) Thomas Oellerich et al. Nature Communications
- hCINAP regulates the DNA-damage response and mediates the resistance of acute myelocytic leukemia cells to therapy
- (2019) Ruidan Xu et al. Nature Communications
- Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial
- (2019) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
- (2018) Lorenzo Galluzzi et al. CELL DEATH AND DIFFERENTIATION
- Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
- (2018) Gail J Roboz et al. HAEMATOLOGICA
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
- (2018) Ibrahim Aldoss et al. HAEMATOLOGICA
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- Efficacy of azacitidine is independent of molecular and clinical characteristics-an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature
- (2018) Andrea Kuendgen et al. Oncotarget
- Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia
- (2018) Gail J Roboz et al. HAEMATOLOGICA
- Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
- (2018) Ibrahim Aldoss et al. HAEMATOLOGICA
- Emerging Roles of Nucleoside Transporters
- (2018) Marçal Pastor-Anglada et al. Frontiers in Pharmacology
- Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
- (2018) Anne Kubasch et al. Cancers
- Acute myeloid leukaemia
- (2018) Nicholas J Short et al. LANCET
- Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
- (2018) Daniel A. Pollyea et al. NATURE MEDICINE
- With me or against me: Tumor suppressor and drug resistance activities of SAMHD1
- (2017) Nikolas Herold et al. EXPERIMENTAL HEMATOLOGY
- Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
- (2017) Bruno C. Medeiros et al. HAEMATOLOGICA
- Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Margaret R. O'Donnell et al. Journal of the National Comprehensive Cancer Network
- AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo
- (2017) A Unnikrishnan et al. LEUKEMIA
- Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias
- (2017) Henning D. Popp et al. LEUKEMIA RESEARCH
- Tracing the origins of relapse in acute myeloid leukaemia to stem cells
- (2017) Liran I. Shlush et al. NATURE
- BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia
- (2017) Valérie Vidal et al. Oncotarget
- Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
- (2017) Satoshi Imanishi et al. Oncotarget
- Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis
- (2017) Benny Zhitomirsky et al. Oncotarget
- Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
- (2017) Bruno C. Medeiros et al. HAEMATOLOGICA
- The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year collaborative odyssey
- (2016) J. D. Young BIOCHEMICAL SOCIETY TRANSACTIONS
- Combined Inhibition of DNMT and HDAC Blocks the Tumorigenicity of Cancer Stem-like Cells and Attenuates Mammary Tumor Growth
- (2016) R. Pathania et al. CANCER RESEARCH
- ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression
- (2016) CD Drenberg et al. CTS-Clinical and Translational Science
- Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
- (2016) Gabriela Nestal de Moraes et al. CURRENT DRUG TARGETS
- Lysosomes as mediators of drug resistance in cancer
- (2016) Benny Zhitomirsky et al. DRUG RESISTANCE UPDATES
- Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
- (2016) Wen Li et al. DRUG RESISTANCE UPDATES
- Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5
- (2016) Eun-Hye Hur et al. Oncotarget
- The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer
- (2016) Dan Gao et al. Oncotarget
- A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers
- (2016) Jeannine Diesch et al. Clinical Epigenetics
- DNA damage repair and tolerance: a role in chemotherapeutic drug resistance
- (2016) M. R. Salehan et al. BRITISH JOURNAL OF BIOMEDICAL SCIENCE
- Cellular Uptake of Decitabine by Equilibrative Nucleoside Transporters in HCT116 Cells
- (2015) Kumiko Ueda et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome
- (2015) Ping Wu et al. LEUKEMIA RESEARCH
- Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure
- (2015) Stéphanie Harel et al. LEUKEMIA RESEARCH
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine
- (2015) MIKA HOSOKAWA et al. Oncology Letters
- Role of Microenvironment in Resistance to Therapy in AML
- (2015) Yoko Tabe et al. Current Hematologic Malignancy Reports
- Targeting the Microenvironment in Acute Myeloid Leukemia
- (2015) Armin Rashidi et al. Current Hematologic Malignancy Reports
- Incidence and Burden of the Myelodysplastic Syndromes
- (2015) Christopher R. Cogle Current Hematologic Malignancy Reports
- BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
- (2015) Thomas Cluzeau et al. Oncotarget
- Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines
- (2015) Thomas Cluzeau et al. Oncotarget
- Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance
- (2015) Benny Zhitomirsky et al. Oncotarget
- Constitutive activation of the ATM/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines
- (2014) Satoshi Imanishi et al. BIOCHEMICAL PHARMACOLOGY
- DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance
- (2014) Maria Teresa Esposito et al. CHROMOSOMA
- Why methylation is not a marker predictive of response to hypomethylating agents
- (2014) M. T. Voso et al. HAEMATOLOGICA
- BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
- (2014) J M Bogenberger et al. LEUKEMIA
- Ex vivoactivity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies
- (2014) James M. Bogenberger et al. LEUKEMIA & LYMPHOMA
- Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine
- (2014) Vu H. Duong et al. LEUKEMIA & LYMPHOMA
- Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
- (2014) M. R. Corces-Zimmerman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival and Tamoxifen Resistance
- (2014) Nagireddy Putluri et al. NEOPLASIA
- Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine
- (2014) Auke D Adema et al. SpringerPlus
- Chemotherapy induced DNA damage response
- (2013) Derek Woods et al. CANCER BIOLOGY & THERAPY
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
- (2013) Eleni D. Lagadinou et al. Cell Stem Cell
- Gender, Cytidine Deaminase, and 5-Aza/Decitabine--Letter
- (2013) J. Ciccolini et al. CLINICAL CANCER RESEARCH
- Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
- (2013) R. Z. Mahfouz et al. CLINICAL CANCER RESEARCH
- Mechanisms of resistance to azacitidine in human leukemia cell lines
- (2013) Piyanuch Sripayap et al. EXPERIMENTAL HEMATOLOGY
- Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
- (2013) A Valencia et al. LEUKEMIA
- Synergistic Effect of 5-Azacytidine and NF-κB Inhibitor DHMEQ on Apoptosis Induction in Myeloid Leukemia Cells
- (2013) Tomiteru Togano et al. ONCOLOGY RESEARCH
- Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51
- (2013) Chengzhi Xie et al. PLoS One
- Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis
- (2013) L Steinhart et al. Cell Death & Disease
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- New Insight into P-Glycoprotein as a Drug Target
- (2012) Albert Breier et al. Anti-Cancer Agents in Medicinal Chemistry
- RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia
- (2012) J. Aimiuwu et al. BLOOD
- FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair
- (2012) Yun-Yong Park et al. CARCINOGENESIS
- Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis
- (2012) L. Ouyang et al. CELL PROLIFERATION
- Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
- (2012) Nitzan Gonen et al. DRUG RESISTANCE UPDATES
- Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia
- (2012) C Craddock et al. LEUKEMIA
- Role of Human Nucleoside Transporters in the Uptake and Cytotoxicity of Azacitidine and Decitabine
- (2012) Vijaya L. Damaraju et al. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
- Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers
- (2012) Y Adar et al. Cell Death & Disease
- Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients
- (2011) C. Tibaldi et al. ANNALS OF ONCOLOGY
- Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia
- (2011) Sylvain Thépot et al. CELL CYCLE
- Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
- (2011) K. J. Gotink et al. CLINICAL CANCER RESEARCH
- The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria-mediated apoptosis and DNA damage in p53 mutant leukemic T cells
- (2011) María J. Ruiz-Magaña et al. INTERNATIONAL JOURNAL OF CANCER
- Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
- (2011) Thomas Prébet et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular mechanisms of cisplatin resistance
- (2011) L Galluzzi et al. ONCOGENE
- Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome
- (2011) Taichun Qin et al. PLoS One
- Highly Phosphorylated FOXO3A Is an Adverse Prognostic Factor in Acute Myeloid Leukemia
- (2010) S. M. Kornblau et al. CLINICAL CANCER RESEARCH
- RNA methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage
- (2010) M. Schaefer et al. GENES & DEVELOPMENT
- 3-Deazauridine enhances the antileukemic action of 5-aza-2′-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase
- (2010) Noël J.-M. Raynal et al. LEUKEMIA RESEARCH
- Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression
- (2010) Wioleta Luszczek et al. MOLECULAR CANCER THERAPEUTICS
- Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes
- (2009) T. Nösslinger et al. ANNALS OF ONCOLOGY
- Azacytidine Inhibits RNA Methylation at DNMT2 Target Sites in Human Cancer Cell Lines
- (2009) M. Schaefer et al. CANCER RESEARCH
- Expression of ABCC-Type Nucleotide Exporters in Blasts of Adult Acute Myeloid Leukemia: Relation to Long-term Survival
- (2009) Y. Guo et al. CLINICAL CANCER RESEARCH
- Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation
- (2009) M. Rius et al. MOLECULAR CANCER THERAPEUTICS
- Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome
- (2009) S Boehrer et al. ONCOGENE
- Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines
- (2008) T. Qin et al. BLOOD
- Human Multidrug Resistance Protein 7 (ABCC10) Is a Resistance Factor for Nucleoside Analogues and Epothilone B
- (2008) E. Hopper-Borge et al. CANCER RESEARCH
- Tumor resistance to apoptosis
- (2008) Simone Fulda INTERNATIONAL JOURNAL OF CANCER
- Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
- (2008) Gautam Borthakur et al. LEUKEMIA & LYMPHOMA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search